Interferon β-1a in ulcerative colitis: A placebo controlled, randomised, dose escalating study

Gut

Volumn 52, Issue 9, 2003, Pages 1286-1290

  Nikolaus, S ^a   Rutgeerts, P ^b   Fedorak, R ^c   Steinhart, A H ^d   Wild, G E ^e   Theuer, D ^f   Mohrle J ^g   Schreiber, S ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; AGED; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOMODULATION; INJECTION PAIN; INJECTION SITE; MALE; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; ULCERATIVE COLITIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED;

EID: 0042386679     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.9.1286     Document Type: Article

References (31)

1. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995;101:428-35.
2. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, et al. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994;12:290-304.
3. Cassini-Raggi V, Kam L, Chong YJ, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-40.
4. Sher ME, D'Angelo AJ, Stein TA, et al. Cytokines in Crohn's colitis. Am J Surg 1995;169:133-6.
5. Hyams JS, Fitzgerald JE, Wyzga N, et al. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1995;21:419-25.
6. Nakamura M Saito H, Kasanuki J, et al. Cytokine production in patients with inflammatory bowel disease. Gut 1992;33:933-7.
7. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9.
8. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
9. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
10. Oren R, Arber N, Odes S, et al. Methotrexate in chronic ulcerative colitis: a double blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
11. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40.
12. Panitch HS, Folus JS, Johnson KP. Recombinant IFN-β inhibits IFN-gamma production in MS. Ann Neurol 1987;22:137.
13. Brod SA, Marshall GD Jr, Henninger EM, et al. Interferon-β 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996;46:1633-8.
14. Devajyothi C, Kalvakolanu I, Babcock GT, et al. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 1993;268:18794-800.
15. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-27.
16. Schnaper HW, Aune TM, Pierce CW. Suppressor T cell activation by human leukocyte IFN. J Immunol 1983;131:2301-6.
17. Saksela ET, Timonen T, Cantell K. Human natural killer cell activity is augmented by IFN via recruitment of 'pre-NK' cells. Scand J Immunol 1979;10:251-6.
18. James RI, Menaya J, Hudson K, et al. Role of protein kinase C in induction of gene expression and inhibition of cell proliferation by interferon alpha. Eur J Biochem 1992;209:813-22.
19. Palleroni AV, Aglione A, Labow M, et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997;17(suppl 1):S23-7.
20. Lowenthal JW, York JJ, O'Neil TE, et al. In vivo effects of chicken interferon-gamma during infection with Eimeria. J Interferon Cytokine Res 1997;17:551-8.
21. Yin K, Hock CE, Lai PS, et al. Role of interferon-gamma in lung inflammation following cecal ligation and puncture in rats. Shock 1999;12:215-21.
22. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002 15;185:1490-501.
23. Sumer N, Palabiyikoglu M. Induction of remission by IFN-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602.
24. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long- term pilot trial. Aliment Pharmacol Ther 2002;16:1233-9.
25. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
26. Sachs L. Angewandte Statistik, 7th edn. Heidelberg: Springer, 1992.
27. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon- β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
28. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon beta- 1a dose response in relapsing-remitting MS. The OWIMS study. Neurology 1999;53:679-86.
29. Chofflon M. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 2000;7:369-80.
30. Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-15.
31. Ruther U, Nunnensiek C, Muller HA, et al. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Hepatogastroenterology 1998;45:691-89.